Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?

Should lipidologists consider other markers such as apoB as well as LDL-C for reducing CV risk in diabetes and hypertriglyceridemia?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Alberico Catapano, PhD

Alberico Catapano, PhD

Full Professor of Pharmacology University of Milano Director, Laboratory for the Study of Lipoproteins and Atherosclerosis Director, Center for the Study of Atherosclerosis of the Italian Society of Atherosclerosis